November 17, 2025

DaVita Inc. (DVA) Investor Outlook: Navigating a 18.88% Potential Upside in the Healthcare Sector

DaVita Inc. (NYSE: DVA), a key player in the healthcare sector, specializes in providing kidney dialysis services across the United States. With a market capitalization of $8.69 billion, DaVita operates..

Medtronic plc (MDT) Stock Analysis: Exploring the Growth Potential and Analyst Ratings

Medtronic plc (MDT) stands as a formidable giant in the healthcare sector, particularly within the medical devices industry. With a market capitalization of a staggering $123.31 billion, this Ireland-headquartered company..

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a 11.13% Potential Upside in the Medical Devices Sector

Bio-Rad Laboratories, Inc. (NYSE: BIO), a venerable name in the healthcare sector, particularly in medical devices, is drawing investor attention with its substantial market cap of $8.49 billion and a..

Revvity, Inc. (RVTY): Investor Outlook with a 22.58% Potential Upside

Revvity, Inc. (RVTY), a prominent player in the healthcare sector, is capturing investor attention with its robust diagnostics and research offerings. With a market capitalization of $10.59 billion, the company..

Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating Growth Potential with an 8.17% Upside

Krystal Biotech, Inc. (NASDAQ: KRYS) is making waves in the healthcare sector, particularly within the biotechnology industry. With a market capitalization of $5.97 billion, this Pittsburgh-based company is dedicated to..

Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Leader with a Promising 7.11% Upside

Exelixis, Inc. (NASDAQ: EXEL) is a name that resonates significantly within the biotechnology sector, especially for investors seeking opportunities in healthcare innovation. With a market capitalization of $11.35 billion, Exelixis..

Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A Promising Upside with 20.54% Potential for Investors

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) presents an intriguing opportunity for investors seeking exposure to the healthcare sector, specifically within the specialty and generic drug manufacturing industry. With a market capitalization..

Encompass Health Corporation (EHC) Stock Analysis: Strong Buy Ratings and 23.69% Upside Potential

Encompass Health Corporation (NYSE: EHC), a leader in the healthcare sector, continues to capture investor attention with its robust financial standing and promising growth potential. Specializing in post-acute healthcare services,..

Solventum Corporation (SOLV) Stock Analysis: Uncovering a Potential 11% Upside

Solventum Corporation (SOLV), a prominent player in the healthcare sector, has been capturing the attention of investors due to its diverse operations and promising stock performance. As a company specializing..

Medpace Holdings, Inc. (MEDP) Stock Analysis: Navigating Highs with Robust Growth and Cautious Analyst Ratings

Medpace Holdings, Inc. (NASDAQ: MEDP) continues to be an intriguing player in the healthcare sector, specifically within the diagnostics and research industry. As a company offering comprehensive clinical development services,..

Guardant Health, Inc. (GH) Stock Analysis: A Promising Outlook in Precision Oncology with 38.50% Revenue Growth

Guardant Health, Inc. (NASDAQ: GH), a leader in the precision oncology space, is making waves with its innovative diagnostic solutions, positioning itself as a noteworthy player for investors eyeing the..

Align Technology, Inc. (ALGN)

⚠️ No article content returned.

..

Oscar Health, Inc. (OSCR) Stock Analysis: Navigating the -7.24% Potential Downside and Future Prospects

Oscar Health, Inc. (NYSE: OSCR) stands as a notable player in the healthcare technology sector, offering a suite of health plans and innovative platforms aimed at enhancing the healthcare experience..

Alkermes plc (ALKS) Stock Analysis: Investors Eye 52% Potential Upside

Alkermes plc (NASDAQ: ALKS), a prominent player in the healthcare sector specializing in drug manufacturing, is capturing the attention of investors with its impressive growth prospects and solid market positioning...

Verona Pharma plc (VRNA): Investor Outlook in the Biotech Space with Strong Technical Momentum

Verona Pharma plc (NASDAQ: VRNA), a burgeoning force in the biotechnology sector, is capturing investor attention with its strategic focus on treating respiratory diseases, an area marked by significant unmet..

Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring a 434% Revenue Growth in the Booming Biotech Sector

Avidity Biosciences, Inc. (RNA), a notable player in the biotechnology sector, is making waves with its innovative approach to RNA therapeutics. As the company continues to advance its proprietary Antibody..

Bio-Techne Corp (TECH) Stock Analysis: Strong Buy Ratings and 16.48% Potential Upside Capture Investor Attention

Bio-Techne Corporation (NASDAQ: TECH) stands as a compelling focus for investors keen on the healthcare sector, particularly within the biotechnology industry. With a market capitalization of $9.46 billion, Bio-Techne has..

Cytokinetics, Incorporated (CYTK) Stock Analysis: Potential 18% Upside Amidst Robust Revenue Growth

Cytokinetics, Incorporated (NASDAQ: CYTK), a prominent player in the healthcare sector, is making waves in the biotechnology industry with its innovative approach to muscle-related therapies. With a market capitalization of..

AptarGroup, Inc. (ATR) Stock Analysis: A 36.10% Potential Upside in the Healthcare Sector

AptarGroup, Inc. (NYSE: ATR), a prominent player in the healthcare sector, stands out with a robust potential upside of 36.10% according to the average analyst target price. This makes it..

Agilent Technologies, Inc. (A) Stock Analysis: Navigating Growth in the Diagnostics & Research Sector

Agilent Technologies, Inc. (NYSE: A) stands as a formidable player within the healthcare sector, specifically in the Diagnostics & Research industry. With its headquarters in Santa Clara, California, Agilent has..

Search

Funds

November 17, 2025

Search

Funds

November 17, 2025

FTSE 100

Funds